Artificial Intelligence In Genomics Market

In the Artificial Intelligence in Genomics Market, North America holds the largest market share valued at 0.94 USD Billion in 2024.

Major Players

Key artificial intelligence in genomics market players include Thermo Fisher Scientific, iCarbonX, Grail, and other players. Players incorporate artificial intelligence to enhance data interpretation, improve accuracy in genomic sequencing, and streamline workflows in genomic laboratories.

Market Size, Forecast and Growth Rate

2024 Market Size: USD 2.35 Billion

2035 Market Size: USD 25 Billion

CAGR 2025 to 2035: 23.98%

Largest Regional Market Share in 2024: North America

Key Artificial Intelligence in Genomics Market Trends Highlighted

The Artificial Intelligence in Genomics Market is experiencing significant growth driven by several key market drivers. Increased investment in research and development, particularly in the life sciences sector, has fueled the integration of AI technologies into genomic analyses. This is largely due to the growing demand for personalized medicine, which aims to tailor treatment plans based on individual genetic profiles. As healthcare systems shift towards precision medicine, AI is playing a vital role in processing large amounts of genomic data, thereby enhancing diagnostic accuracy and treatment efficacy. 

Recently, trends in the global market indicate a significant uptick in the adoption of machine learning algorithms and natural language processing tools in genomics research and clinical applications. Research institutions and healthcare providers are increasingly utilizing these advanced technologies to streamline genomic data interpretation and improve patient outcomes. The rising pressure to reduce healthcare costs while enhancing quality of care is also propelling the demand for efficient AI solutions in genomics.

Overall, the synergy between AI advancements and genomics is paving the way for transformative changes in healthcare and research on a global scale, hinting at a promising future for this market.

The Global Artificial Intelligence in Genomics Market Industry is projected to experience substantial growth over the next decade. With a current valuation of 2.35 USD Billion in 2024, the market is expected to expand to 25 USD Billion by 2035. This growth trajectory indicates a robust compound annual growth rate (CAGR) of 23.98% from 2025 to 2035, reflecting the increasing integration of AI technologies in genomic research and applications. Such projections underscore the transformative potential of AI in enhancing genomic analyses and personalized medicine.

Recent advancements in artificial intelligence technologies are propelling the Global Artificial Intelligence in Genomics Market Industry forward. Machine learning algorithms and deep learning techniques are being utilized to analyze vast genomic datasets, facilitating the identification of genetic variants associated with diseases. These innovations enhance the accuracy and efficiency of genomic analyses, potentially leading to breakthroughs in disease prevention and treatment. The market is expected to grow significantly, with a projected CAGR of 23.98% from 2025 to 2035, indicating a robust future driven by technological progress.

The increasing awareness of genetic disorders among the global population is significantly influencing the Global Artificial Intelligence in Genomics Market Industry. As individuals become more informed about the implications of genetic testing, there is a rising demand for genomic solutions that can identify predispositions to various conditions. This awareness drives healthcare providers to integrate AI technologies into their genomic services, enhancing diagnostic capabilities. Consequently, the market is poised for growth, as more individuals seek personalized insights into their genetic health, thereby expanding the scope of genomic applications.

The Global Artificial Intelligence in Genomics Market Industry is experiencing a notable surge in demand for personalized medicine. This trend is largely driven by advancements in genomics, which enable tailored treatments based on individual genetic profiles. As healthcare systems increasingly adopt AI technologies to analyze genomic data, the market is projected to reach 2.35 USD Billion in 2024. This shift towards personalized approaches not only enhances patient outcomes but also optimizes resource allocation within healthcare systems, suggesting a transformative impact on treatment paradigms.

Investment in genomic research is a critical driver for the Global Artificial Intelligence in Genomics Market Industry. Governments and private entities are allocating substantial funds to genomics initiatives, fostering innovation and collaboration. For instance, various countries are establishing genomic research centers to harness AI capabilities for analyzing genetic data. This influx of funding not only accelerates research but also enhances the development of AI-driven genomic solutions. As a result, the market is anticipated to expand, potentially reaching 25 USD Billion by 2035, reflecting the growing recognition of genomics in healthcare.

Regulatory support for genomic innovations plays a pivotal role in shaping the Global Artificial Intelligence in Genomics Market Industry. Governments worldwide are implementing policies that encourage the development and integration of AI in genomics, streamlining approval processes for genomic technologies. This supportive regulatory environment fosters innovation and attracts investments, facilitating the introduction of novel AI-driven genomic solutions. As a result, the market is likely to witness accelerated growth, driven by a conducive framework that promotes the adoption of advanced genomic technologies.

North America leads this market with a valuation of 0.94 USD billion in 2024 and is expected to expand to 10.73 USD billion by 2035, showcasing its dominance due to strong investments in health technology and research facilities. Europe follows closely, starting at 0.7 USD billion in 2024 and reaching 8.05 USD billion by 2035, reflecting robust research initiatives and collaborations among government and industry stakeholders.

South America, valued at 0.15 USD billion in 2024, is anticipated to grow to 1.75 USD billion by 2035, albeit with slower adoption rates due to less funding in technology. In Asia Pacific, a valuation of 0.5 USD billion in 2024 is expected to rise to 4.45 USD billion by 2035, supported by increasing investment in biotechnology and healthcare sectors, indicating significant growth potential. The Middle East and Africa begin with a valuation of 0.06 USD billion in 2024 and may reach 0.92 USD billion in 2035.

This lower figure highlights the emerging market opportunities in AI-driven genomics which may be further enhanced by increased government support and global collaborations.

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

The Artificial Intelligence in Genomics Market has garnered significant attention over recent years as innovations in AI technology enable new possibilities in genomic research and analysis. The competitive landscape is characterized by a diverse array of players ranging from established biotech firms to emerging tech companies. These entities are increasingly leveraging artificial intelligence to enhance data interpretation, improve accuracy in genomic sequencing, and streamline workflows in genomic laboratories.

Companies are differentiating themselves not only through technological innovation but also by forming strategic partnerships, engaging in mergers and acquisitions, and expanding their service offerings to meet the evolving needs of researchers and healthcare institutions. As the demand for personalized medicine and genomic data analysis grows, the competitive dynamics will continue to evolve with an emphasis on cutting-edge research and application.

Thermo Fisher Scientific is a leading player in the Artificial Intelligence in Genomics Market, known for its robust portfolio of genomic solutions and advanced technologies. The company has established a strong market presence by effectively integrating AI with its extensive tools for sequencing, genotyping, and molecular analysis. Thermo Fisher Scientific's strength lies in its ability to deliver comprehensive solutions that cater to various stages of the genomic research workflow, from sample preparation to data analysis.

By investing in research and development, the company has been able to enhance its capabilities in machine learning and data analytics, thus improving the accuracy and efficiency of genomic tests. Furthermore, its global reach and established relationships with research institutions and healthcare providers enable Thermo Fisher Scientific to maintain a steady market position and continue driving advancements in genomic AI applications.

iCarbonX is an important biotechnology company based in Shenzhen, known for its integration of artificial intelligence with genomic and multi-omics data to provide personalized health insights. Established in 2015 by former BGI CEO Jun Wang, the company’s premier platform, Meum, employs AI to assess genomic, proteomic, and behavioral data, providing customized health recommendations. The organization specializes in creating AI-driven tools for data mining, predictive modeling, and visualization, establishing itself as a significant contributor to precision health and digital genomics.

Supported by prominent investors and strategic partnerships, iCarbonX has broadened its international footprint through initiatives such as the Digital Life Alliance, working alongside organizations like SomaLogic and PatientsLikeMe. The acquisition of Israel-based Imagu Vision Technologies has further enhanced its AI and image-processing capabilities, solidifying its position as a leader in the evolving landscape of AI in genomics.